GlassScriptPhysician profile
James B Tilley
NPI 1932178332
$7,668.48
in general payments reported to CMS, 2019-2025
50 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 95% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $774 · 2021: $1,115 · 2022: $1,040 · 2023: $1,138 · 2024: $1,186 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,020.98 | 2019-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $901.50 | 2019-2025 | |
| Novo Nordisk INC | $720.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $666.12 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $637.36 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $427.15 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.71 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $254.21 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $224.62 | 2024-2025 | Rexulti |
| Amgen INC. | $203.82 | 2019-2024 | Repatha, Otezla |
| Corcept Therapeutics | $189.46 | 2025 | Korlym |
| Lundbeck LLC | $175.63 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.19 | 2022-2025 | Caplyta |
| Allergan, INC. | $151.66 | 2019-2020 | |
| Amarin Pharma, INC. | $114.70 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.